KCNV2-Deficient Retinal Organoid Model of Cone Dystrophy—In Vitro Screening for AAV Gene Replacement Therapy
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms27010449 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Sophie L Busson und 11 weiteren Autor:innen. Beteiligte Einrichtung: MeiraGTx UK II, 34-38 Provost Street, London N1 7NG, UK. Hauptthemen laut MEDLINE: Dependovirus, Organoids, Genetic Therapy, Potassium Channels, Voltage-Gated. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MeiraGTx.
Abstract (Originalsprache)
KCNV2 encodes Kv8.2, an electrically silent voltage-gated potassium channel subunit that is expressed in photoreceptors. Disease-causing variants in KCNV2 cause a monogenic disorder which is classified clinically as cone dystrophy with supernormal rod response (CDSRR). Here, we generated KCNV2-deficient human retinal organoids as a tool for gene therapy vector potency assessment. The organoids were derived from two separate sources: by generating IPSCs from patient blood and by gene editing of a control cell line. Eight KCNV2 gene therapy vectors were assessed in retinal organoids; Kv8.2 protein levels and its in situ interactions with potassium channel binding partners were quantitatively assessed. We show significant enhancements in vector potency and specificity by transgene codon optimisation and the use of the photoreceptor-specific rhodopsin kinase (RK) promoter, respectively. Single-cell RNA sequencing was performed in transduced retinal organoids to assess the performance of the AAV vectors at single-cell resolution. KCNV2-deficient photoreceptors had an upregulation in genes associated with apoptosis, oxidative stress, and hypoxia pathways which were partially restored in AAV-KCNV2 transduced photoreceptors. These data show how human retinal organoids can be used to evaluate AAV gene therapy vector potency in vitro in a physiologically relevant model for the selection of lead therapeutic candidates and to help minimise the use of animals in preclinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MeiraGTx UK II, 34-38 Provost Street, London N1 7NG, UK.
- Genome Centre, Blizard Institute, Queen Mary University of London, London E1 2AT, UK.
- Moorfields Eye Hospital, 162 City Road, London EC1V 2PD, UK.
- UCL Institute of Ophthalmology, University College London, London EC1V 9LF, UK.
ORCID-Profile: Toyin Adefila-Ideozu, Sophia El Alami, James Boot
Förderung
- MeiraGTx
Zitieren
APA
Busson, S. L., Naeem, A., Ferrara, S., Sarcar, S., Adefila-Ideozu, T., Wells, S., El Alami, S., Boot, J., Sladen, P. E., Michaelides, M., Georgiadis, A., & Lane, A. (2025). KCNV2-Deficient Retinal Organoid Model of Cone Dystrophy—In Vitro Screening for AAV Gene Replacement Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27010449
Vancouver
Busson SL, Naeem A, Ferrara S, Sarcar S, Adefila-Ideozu T, Wells S, et al. KCNV2-Deficient Retinal Organoid Model of Cone Dystrophy—In Vitro Screening for AAV Gene Replacement Therapy. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms27010449
BibTeX
@article{Busson2025,
author = {Busson, Sophie L and Naeem, Arifa and Ferrara, Silvia and Sarcar, Shilpita and Adefila-Ideozu, Toyin and Wells, Sarah and El Alami, Sophia and Boot, James and Sladen, Paul E and Michaelides, Michel and Georgiadis, Anastasios and Lane, Amelia},
title = {KCNV2-Deficient Retinal Organoid Model of Cone Dystrophy—In Vitro Screening for AAV Gene Replacement Therapy},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms27010449}
}
EUVIMED